Alert over JAK inhibitor's blood clot risk

The TGA says patients on high doses of tofacitinib need to be warned

Patients on the Janus kinase inhibitor tofacitinib should be monitored, and warned about signs and symptoms of pulmonary embolism, the TGA says.

Blood clot

The product information has been updated to include details from an ongoing safety study that linked high doses (10mg twice daily) to increased risk of blood clots and death.

The sponsor of tafacitinib (Xeljanz), Pfizer Australia, wrote to doctors in March, saying that a clinical trial had found an increased risk of clots in the lung and overall mortality when a 10mg twice-daily dose was